Patents Assigned to Gencia Corporation
-
Patent number: 9707244Abstract: The present invention relates to the compositions and methods for treating or alleviating conditions that affect the epidermis (e.g., wrinkles, sun damaged skin, symptoms of aged skin, or the like).Type: GrantFiled: March 14, 2014Date of Patent: July 18, 2017Assignee: Gencia CorporationInventors: Shaharyar Khan, Arthur Glenn Romero, Mikael C. Herlevsen
-
Patent number: 9434753Abstract: The invention discloses creatine derivatives that are represented by Formula (I), Formula (II), and Formula (III); wherein Z is a functional group; Y is a mitochondrial targeting agent, a cationic ammonium group, or a polypeptide containing at least one positively charged amino acid residue; each R1 is independently hydrogen, alkyl, or a phosphate group; R2 a linker; R3 is a spacer group; R4 is hydrogen, alkyl, aryl, or heterocyclic; or R4 and R1, or R4 and R3, together with the nitrogen atoms to which they are attached form a heterocyclic ring, and W is hydrogen or alkyl.Type: GrantFiled: September 18, 2012Date of Patent: September 6, 2016Assignee: Gencia CorporationInventors: Shaharyar M. Khan, Robert Gadwood, Arthur Glenn Romero
-
Patent number: 8952133Abstract: Methods and compositions for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal.Type: GrantFiled: February 17, 2012Date of Patent: February 10, 2015Assignee: Gencia CorporationInventor: Shaharyar Khan
-
Patent number: 8927691Abstract: Methods and compositions for modifying the metabolism of a subject are provided. One embodiment provides a recombinant polypeptide having a polynucleotide-binding domain, a protein transduction domain, and a targeting domain. In a preferred embodiment, the polynucleotide-binding domain includes one or more HMG box domains.Type: GrantFiled: March 13, 2012Date of Patent: January 6, 2015Assignee: Gencia CorporationInventor: Shaharyar Khan
-
Patent number: 8906390Abstract: Compositions and methods for delivering cargo to cells are provided. One aspect provides a synthetic vesicle containing caveolin 1 or a fragment thereof in an amount effective to form lipid rafts in the vesicle. The synthetic vesicles can be used to deliver polynucleotides, proteins, therapeutic agents, or a combination thereof to specific membrane-bound compartments of a cell. In certain aspects, the synthetic vesicles can deliver cargo to cellular organelles such as mitochondria.Type: GrantFiled: March 26, 2007Date of Patent: December 9, 2014Assignee: Gencia CorporationInventor: Shaharyar Khan
-
Publication number: 20140113853Abstract: Methods and compositions for modifying the metabolism of a subject are provided. One embodiment provides a recombinant polypeptide having a polynucleotide-binding domain, a protein transduction domain, and a targeting domain. In a preferred embodiment, the polynucleotide-binding domain includes one or more HMG box domains.Type: ApplicationFiled: November 18, 2013Publication date: April 24, 2014Applicant: GENCIA CORPORATIONInventor: Shaharyar Khan
-
Publication number: 20140045798Abstract: The present invention provides a compound of Formula Ia, wherein R1 is H or phosphate and the double bond is between N1 and C1 or between N2 and C1; R2 is a mitochondrial targeting moiety; R3 an alkyl, alkylaryl, alkylheteroaryl spacer group, a cleavable linker, or absent; R4 is H or an alkyl, aryl, or heteroaryl group; and R5 is alkyl, aryl, or heteroaryl; or N1 C1, and N3 together form a heterocyclic ring containing at least 5 atoms, wherein N1, N3, and R1-R5 are as defined above, or N3 and R5 together form a heterocyclic ring containing at least four atoms; or a pharmaceutically acceptable salt or prodrug thereof.Type: ApplicationFiled: October 18, 2013Publication date: February 13, 2014Applicant: Gencia CorporationInventor: Shaharyar Khan
-
Patent number: 8541550Abstract: Methods and compositions for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal. Methods for modifying the genome of non-nuclear organelles are also provided.Type: GrantFiled: August 19, 2011Date of Patent: September 24, 2013Assignee: Gencia CorporationInventor: Shaharyar Khan
-
Patent number: 8507277Abstract: Methods and compositions for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal. Methods for modifying the genome of non-nuclear organelles are also provided.Type: GrantFiled: March 24, 2006Date of Patent: August 13, 2013Assignee: Gencia CorporationInventor: Shaharyar Khan
-
Patent number: 8470972Abstract: Methods and compositions for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal. Methods for modifying the genome of non-nuclear organelles are also provided.Type: GrantFiled: June 29, 2011Date of Patent: June 25, 2013Assignee: Gencia CorporationInventor: Shaharyar Khan
-
Publication number: 20130072462Abstract: The present invention provides a compound of Formula 1a, wherein R1 is H or phosphate and the double bond is between N? and C? or between N2 and C1; R2 is a mitochondrial targeting moiety; R3 an alkyl, alkylaryl, alkylheteroaryl spacer group, a cleavable linker, or absent; R4 is H or an alkyl, aryl, or heteroaryl group; and R5 is alkyl, aryl, or heteroaryl; or N? C?, and N3 together form a heterocyclic ring containing at least 5 atoms, wherein N1, N3, and R1-R5 are as defined above, or N3 and R5 together form a heterocyclic ring containing at least four atoms; or a pharmaceutically acceptable salt or prodrug thereof.Type: ApplicationFiled: August 17, 2012Publication date: March 21, 2013Applicant: Gencia CorporationInventor: Shaharyar Khan
-
Patent number: 8133733Abstract: Methods and compositions for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal.Type: GrantFiled: October 31, 2007Date of Patent: March 13, 2012Assignee: Gencia CorporationInventor: Shaharyar Khan
-
Patent number: 8062891Abstract: Methods and compositions for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal. Methods for modifying the genome of non-nuclear organelles are also provided.Type: GrantFiled: October 31, 2007Date of Patent: November 22, 2011Assignee: Gencia CorporationInventor: Shaharyar Khan
-
Patent number: 8039587Abstract: Methods and compositions for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal. Methods for modifying the genome of non-nuclear organelles are also provided.Type: GrantFiled: October 25, 2004Date of Patent: October 18, 2011Assignee: Gencia CorporationInventor: Shaharyar Khan
-
Publication number: 20100179106Abstract: Compositions and methods for treating mitochondrial disorders are provided. The compositions include compounds having a mitochondrial targeting moiety, for example a lipophilic cation. Certain compounds are effective for increasing the ratio of phosphocreatine/creatine in a host, for example a mammal. Other compounds decrease the ratio of phophocreatine/creating in a host. An exemplary compound is defined by the following structure (Formula Ia): wherein R1 is H or phosphate and the double bond is between N1 and C1 or between N2 and C1; R2 is a mitochondrial targeting moiety; R3 an alkyl, alkylaryl, alkylheteroaryl spacer group, a cleavable linker, or absent; R4 is H or an alkyl, aryl, or heteroaryl group; and R5 is alkyl, aryl, or heteroaryl; or N1 C1, and N together form a heterocyclic ring containing at least 5 atoms, wherein N1, N3, and R1-R5 are as defined above, or N3 and R5 together form a heterocyclic ring containing at least four atoms; or a pharmaceutically acceptable salt or prodrug thereof.Type: ApplicationFiled: September 8, 2008Publication date: July 15, 2010Applicant: Gencia CorporationInventor: Shaharyar Khan
-
Publication number: 20060211647Abstract: Methods and compositions for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal. Methods for modifying the genome of non-nuclear organelles are also provided.Type: ApplicationFiled: March 24, 2006Publication date: September 21, 2006Applicant: GENCIA CORPORATIONInventor: Shaharyar Khan